Lung cancer immune study aims to unlock biomarkers for better treatment
NCT ID NCT04432142
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the immune system changes in 45 people with stage III non-small cell lung cancer who receive chemoradiation followed by the drug durvalumab. Researchers want to find immune markers that could predict how well the treatment works. The goal is to improve future therapies by understanding these immune effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab
What this could lead to
If successful, this study could identify immune biomarkers that help predict which patients benefit most from durvalumab after chemoradiation, improving personalized treatment.
What could go wrong
This is a small, early-phase observational study (45 participants) focused on immune profiling, not on proving treatment effectiveness. Results may not lead to immediate clinical changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maastricht Radiation Oncology (MAASTRO clinic)
Maastricht, 6229 ET, Netherlands